Windlas Biotech Ltd
As of 20 Nov 2026, Windlas Biotech is in Stage 3, the topping phase, now in week 2 (since 11 Nov 2026). It closed at ₹961, 16.8% below its 52-week high and above its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. More about the company
Pro read
ProWINDLAS's uptrend is tiring: 2 weeks into a top. A topping stock either breaks back out or rolls over into a decline, and the next few weeks usually settle which.
Its relative strength is 77 of 99, above the middle among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.
Is WINDLAS early, or has it already run? Pro answers that for every NSE stock, after every close.
WINDLAS among Pharmaceuticals51st of 118 by relative strength
All 118 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | BLISSGVS | Stage 2 · wk 49 | 99 | +4.6% |
| 2 | KPL | Stage 2 · wk 44 | 99 | +20.5% |
| 3 | FREDUN | Stage 2 · wk 33 | 98 | +24.0% |
| 4 | VENUSREM | Stage 3 · wk 10 | 98 | −1.5% |
| 5 | RUBICON | Stage 3 · wk 4 | 98 | +18.7% |
| 6 | SAKAR | Stage 2 · wk 55 | 98 | +13.1% |
| 7 | BAFNAPH | Stage 2 · wk 23 | 98 | +1.9% |
| 8 | INDSWFTLAB | Stage 2 · wk 23 | 98 | −7.4% |
| …51 | WINDLAS | Stage 3 · wk 2 | 77 | +9.1% |
Mutual fund holdings
Held by 3 mutual funds in portfolios to October 2026: 2 active funds and 1 index funds and ETFs.
In October, among active funds: 1 increased.
All 3 funds and what each did in October
Mutual funds holding WINDLAS: the ten largest and the month’s moves →
Windlas Biotech: quick answers
What stage is Windlas Biotech in?
As of 20 Nov 2026, Windlas Biotech (WINDLAS) is in Stage 3, the topping phase. It entered Stage 3 on 11 Nov 2026 and is in week 2. What the four stages mean
Is Windlas Biotech in an uptrend?
Its uptrend has stalled. Windlas Biotech is in Stage 3, the topping phase that follows an advance. It trades 9.2% above its 200-day average, which is rising.
How far is Windlas Biotech from its 52-week high?
Windlas Biotech closed at ₹961 on 20 Nov 2026, 16.8% below its 52-week high of ₹1,155. Its 52-week low is ₹706.
How has Windlas Biotech performed over the past year?
As of 20 Nov 2026, Windlas Biotech is up 15.7% over the past year and up 20.9% so far in 2026.
Which sector and industry is Windlas Biotech in?
Windlas Biotech is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals
About this companyHealth Care· Pharmaceuticals
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradun, India.
Visit company website →All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.